TY - JOUR
T1 - Corrigendum to “Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination
T2 - A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission” [Journal of Controlled Release 294 (2019)216–225](S0168365918307302)(10.1016/j.jconrel.2018.12.027)
AU - Mandal, Subhra
AU - Kang, Guobin
AU - Prathipati, Pavan Kumar
AU - Zhou, You
AU - Fan, Wenjin
AU - Li, Qingsheng
AU - Destache, Christopher J.
N1 - Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/6/28
Y1 - 2019/6/28
N2 - The authors regret that the following errors occurred in following subsections. Changes can be found in italics below: 2.6. Pharmacokinetic (PK)assessment in humanized mice Further, all mice in ARV NPs and ARV solution treatment group, received subcutaneously (SubQ)TAF+FTC NPs and TAF+FTC along with elvitegavir (EVG)in solution (at 200 mg/kg each drug), respectively. However, EVG is not related to present study, has no drug-drug interactions [1]and a complete PK study related to EVG has been previously published. Hence, EVG has not been discussed any further in the present article [2,3]. 2.9. Ethics statement Last sentence: All PK in vivo experiments (except the group of mice that received drugs in solution)were performed in accordance with Creighton University IACUC approved protocol (Protocol #0989). References [1]AIDSinfo, Drug Interactions between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents). in: U.S.D.o.H.H. Services (Ed.), U.S. Department of Health & Human Services, Washington, DC, USA, 2018. [2]P.K. Prathipati, S. Mandal, G. Pon, R. Vivekanandan, C.J. Destache, Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model, Pharm Res, 34 (2017)2749-2755. [3]S. Mandal, P.K. Prathipati, G. Kang, Y. Zhou, Z. Yuan, W. Fan, Q. Li, C.J. Destache, Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission, AIDS, 31 (2017)469-476. The authors would like to apologise for any inconvenience caused.
AB - The authors regret that the following errors occurred in following subsections. Changes can be found in italics below: 2.6. Pharmacokinetic (PK)assessment in humanized mice Further, all mice in ARV NPs and ARV solution treatment group, received subcutaneously (SubQ)TAF+FTC NPs and TAF+FTC along with elvitegavir (EVG)in solution (at 200 mg/kg each drug), respectively. However, EVG is not related to present study, has no drug-drug interactions [1]and a complete PK study related to EVG has been previously published. Hence, EVG has not been discussed any further in the present article [2,3]. 2.9. Ethics statement Last sentence: All PK in vivo experiments (except the group of mice that received drugs in solution)were performed in accordance with Creighton University IACUC approved protocol (Protocol #0989). References [1]AIDSinfo, Drug Interactions between Nucleoside Reverse Transcriptase Inhibitors and Other Drugs (Including Antiretroviral Agents). in: U.S.D.o.H.H. Services (Ed.), U.S. Department of Health & Human Services, Washington, DC, USA, 2018. [2]P.K. Prathipati, S. Mandal, G. Pon, R. Vivekanandan, C.J. Destache, Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model, Pharm Res, 34 (2017)2749-2755. [3]S. Mandal, P.K. Prathipati, G. Kang, Y. Zhou, Z. Yuan, W. Fan, Q. Li, C.J. Destache, Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission, AIDS, 31 (2017)469-476. The authors would like to apologise for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85065240978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065240978&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2019.05.002
DO - 10.1016/j.jconrel.2019.05.002
M3 - Comment/debate
C2 - 31082646
AN - SCOPUS:85065240978
SN - 0168-3659
VL - 304
SP - 101
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -